Award Directory

The Advanced Research Projects Agency for Health (ARPA-H) funds high-impact research and development that would otherwise never happen. These bold, innovative efforts are meant to solve the most challenging health problems, spanning translational medicine, platform applications, and transformations in patient outcomes.

Use the filters below to search by keyword, award type, managing office, or year to find leading institutions, innovative companies, and pioneering researchers working across our portfolio.

Filter by

Mission Office Award

Resilient Systems Project

HYPERDRIVE: High-Performance Processors to Drive AI Revolution in Biomedical Discovery

AI has shown enormous promise to speed up biomedical research and development. Yet, its potential is limited by relying on graphics processing units (...
February 11, 2026

Program Award

OCULAB

TEARWISE: Tear-Film Electronic Active Release and Wireless Immuneshielded Sensing

The team is developing a new sensor made from DNA structures to measure tear osmolarity (how salty the tears are), a key sign of dry eye disease. The ...
January 30, 2026

Program Award

OCULAB

COSMIC: Closed-Loop Sensing and Microdosing for Dry Eye and Systemic Disease Management

Lacristat is creating tiny, nanostructured electrodes that can detect signs of dry eye and overall metabolic health, including biomarkers for women’s ...
January 29, 2026

Program Award

LIGHT

CLARIUM: Congenital Lymphatic Anomaly Genomic Consortium

Columbia University in New York City will use advanced cell-based and cell-free DNA panels to precisely diagnose and classify pediatric lymphatic anom...
November 13, 2025

Program Award

LIGHT

Devices for Assessment of Thoracic Duct Structure/Function in Central Conducting Lymphatic Anomaly

3DT Holdings, LLC, in San Diego aims to develop a first-in-class interventional device to measure lymphatic flow and obstruction in real time, so clin...
November 7, 2025

Program Award

LIGHT

LANTERN: Lymphatic disease Advancements with Nanotechnology, Translational Epigenetics, and Research in Genetics

Weill Cornell Medicine in New York City will develop a comprehensive diagnostic platform that integrates AI-enabled biomarker technologies, high-resol...
November 5, 2025

Program Award

CATALYST

PREDICTS: Pharmacological Research and Evaluation through Digital Integration and Clinical Trial Simulation

Deep Origin in San Francisco, with a team comprised of Ginkgo Bioworks, Inc., ImmVue Therapeutics, Modeling Informed Design and Optimization, LLC, Net...
September 30, 2025

Program Award

POSEIDON

Neoplasm Early Prediction Through Use of Neojunction-derivatives and Enzymes

Grafton Biosciences, Inc. in Peachtree Corners, Ga. intends to develop both oral and inhalable sensors that will release tunable reporters for urine-b...
September 30, 2025

Program Award

CATALYST

DeepMesa: Good AI Practice (GAIP) for assured AI-driven ADME-Tox

Black Mesa Technology, Inc., in Bedford, Mass. Intends to establish and document a good experimental practice (GxP) environment to assure quality and ...
September 30, 2025

Program Award

CATALYST

Comprehensive Assessment of cardiac Risk through Data-driven In- SilicO Virtual Ecosystems foR Safety Evaluation

The Jackson Laboratory in Bar Harbor, Maine, with a team comprised of University of Connecticut Health Center, New York Stem Cell Foundation, InSilico...
September 30, 2025

Program Award

POSEIDON

C-DETECT: Cancer Detection for Early Tumors using Enhanced Cell Targeting

Carnegie Mellon University in Pittsburgh, Penn., with its commercial partner Ginkgo Bioworks, aims to develop orally-administered probiotic sensors, w...
September 30, 2025

Program Award

POSEIDON

Novel Approaches to Uncovering Cancer

Owlstone Medical Limited in Cambridge, United Kingdom seeks to develop inhalable sensors for urine-based detection using multiplexed reporters and vol...
September 30, 2025